JP2023513901A5 - - Google Patents
Info
- Publication number
- JP2023513901A5 JP2023513901A5 JP2022548978A JP2022548978A JP2023513901A5 JP 2023513901 A5 JP2023513901 A5 JP 2023513901A5 JP 2022548978 A JP2022548978 A JP 2022548978A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2023513901 A5 JP2023513901 A5 JP 2023513901A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- deuterated
- composition according
- ester
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025202414A JP2026035680A (ja) | 2020-02-14 | 2025-11-25 | タウオパチーの治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976958P | 2020-02-14 | 2020-02-14 | |
| US62/976,958 | 2020-02-14 | ||
| PCT/US2021/017981 WO2021163580A1 (en) | 2020-02-14 | 2021-02-12 | Methods for treating tauopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202414A Division JP2026035680A (ja) | 2020-02-14 | 2025-11-25 | タウオパチーの治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513901A JP2023513901A (ja) | 2023-04-04 |
| JP2023513901A5 true JP2023513901A5 (enExample) | 2024-02-20 |
Family
ID=77273602
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548978A Pending JP2023513901A (ja) | 2020-02-14 | 2021-02-12 | タウオパチーの治療方法 |
| JP2025202414A Pending JP2026035680A (ja) | 2020-02-14 | 2025-11-25 | タウオパチーの治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202414A Pending JP2026035680A (ja) | 2020-02-14 | 2025-11-25 | タウオパチーの治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210251933A1 (enExample) |
| EP (1) | EP4103169A4 (enExample) |
| JP (2) | JP2023513901A (enExample) |
| KR (1) | KR20220140808A (enExample) |
| CN (1) | CN116507325A (enExample) |
| AU (1) | AU2021220981A1 (enExample) |
| CA (1) | CA3171330A1 (enExample) |
| IL (1) | IL295512A (enExample) |
| WO (1) | WO2021163580A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240064584A (ko) * | 2021-02-05 | 2024-05-13 | 레트로토프 인코포레이티드 | 중수소화 아라키돈산을 사용한 신경퇴행성 질환의 치료에 대한 환자의 반응을 평가하는 방법 |
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US11491130B2 (en) | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| US20230165824A1 (en) * | 2021-09-03 | 2023-06-01 | Biojiva Llc | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs |
| CN118201607A (zh) * | 2021-09-03 | 2024-06-14 | 拜奥吉瓦有限责任公司 | 利用氘代pufa抑制细胞功能障碍和细胞死亡的方法、系统和组合物 |
| CA3243042A1 (en) * | 2021-12-21 | 2025-04-08 | Biojiva Llc | METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF INFLAMMATORY DISEASE |
| WO2023192406A2 (en) * | 2022-03-30 | 2023-10-05 | Retrotope, Inc. | Prophylactic methods for treating als |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2493296T3 (en) | 2009-10-30 | 2019-04-15 | Retrotope Inc | REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES |
| US10058522B2 (en) * | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Oxidative retinal diseases |
| US10154983B2 (en) * | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| WO2018094116A1 (en) * | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
| EP3461479B1 (en) * | 2017-09-27 | 2021-06-16 | Julie Blivet | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions |
| EP3806841A1 (en) * | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Decreasing immune activity through modulation of postcellular signaling factors |
-
2021
- 2021-02-12 KR KR1020227031617A patent/KR20220140808A/ko active Pending
- 2021-02-12 CA CA3171330A patent/CA3171330A1/en active Pending
- 2021-02-12 US US17/175,397 patent/US20210251933A1/en not_active Abandoned
- 2021-02-12 JP JP2022548978A patent/JP2023513901A/ja active Pending
- 2021-02-12 EP EP21753302.5A patent/EP4103169A4/en active Pending
- 2021-02-12 AU AU2021220981A patent/AU2021220981A1/en active Pending
- 2021-02-12 WO PCT/US2021/017981 patent/WO2021163580A1/en not_active Ceased
- 2021-02-12 IL IL295512A patent/IL295512A/en unknown
- 2021-02-12 CN CN202180028457.1A patent/CN116507325A/zh active Pending
-
2024
- 2024-07-09 US US18/767,538 patent/US20250177339A1/en active Pending
-
2025
- 2025-11-25 JP JP2025202414A patent/JP2026035680A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019226257B2 (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
| CA2218699C (en) | 1,3-propane diol derivatives as bioactive compounds | |
| CA2607247C (en) | .alpha.-substituted dha derivatives | |
| RU2509071C2 (ru) | Новые липидные соединения | |
| EP2094640A1 (en) | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar). | |
| JP5552314B2 (ja) | 新規脂質化合物 | |
| JP2015527386A5 (enExample) | ||
| ES2733353T3 (es) | Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento | |
| JP2019501135A5 (enExample) | ||
| NZ596386A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| ES2401629B1 (es) | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. | |
| WO1998018751A1 (en) | Presentation of bioactives | |
| JP2020500193A5 (enExample) | ||
| JP2016501248A5 (enExample) | ||
| KR20090077081A (ko) | 지방산 알코올 | |
| JP2018515463A5 (enExample) | ||
| US20100267828A1 (en) | dha derivatives and their use as medicaments | |
| CN115025079A (zh) | 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途 | |
| KR20180010181A (ko) | Apo c3 의 저하를 위한 티아 옥소 화합물의 용도 | |
| US7649103B2 (en) | Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field | |
| JP2018510206A5 (enExample) | ||
| JP2022504707A5 (enExample) | ||
| WO2013037862A1 (fr) | Phosphatidylcholines spécifiques en tant que modulateurs de l'activité du facteur d'activation plaquettaire | |
| CN1187813A (zh) | 作为生物活性化合物的脂肪酸酯 | |
| RU2507193C2 (ru) | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) |